Incyte and Calithera Collaboration Is Fair and Lucrative for Both Firms

Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a Small Molecule Arginase Inhibitor                        
Incyte (INCY) and Calithera Biosciences (CALA) announced a global collaboration and license agreement for the research, development and commercialization of Calithera’s first-in-class, small molecule arginase inhibitor CB-1158 in hematology and oncology.

CB-1158 is currently being studied in a monotherapy dose escalation trial. Additional studies, however, are . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.